^
    Back
    Association details:
    Biomarker:HLA-A*03
    Cancer:Renal Cell Carcinoma
    Drug:Bavencio (avelumab) (PD-L1 inhibitor) +
    Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

    Published date:
    12/09/2021
    Excerpt:
    HLA-A*03 was associated with shorter progression-free survival in patients receiving ICI in the JAVELIN Renal 101 randomised clinical trial for renal cell carcinoma (avelumab plus axitinib; HR 1·59 per HLA-A*03 allele, 1·16–2·16; p=0·0036), but not in those receiving control (sunitinib) therapy....HLA-A*03 is a predictive biomarker of poor response to ICI.
    DOI:
    https://doi.org/10.1016/S1470-2045(21)00582-9